CCS
CRDF icon

Crosspoint Capital Strategies’s Cardiff Oncology CRDF Stock Holding History

Crosspoint Capital Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7
Closed -$3K – 534
2014
Q1 		$3K Hold
7
– – ﹤0.01% 616
2013
Q4 		$3K Buy
+7
New +$3.12K ﹤0.01% 522

Other funds holding CRDF

BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Crosspoint Capital Strategies's CRDF Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of Cardiff Oncology (CRDF) in Q2 2014, closing a stake of 7 shares — an estimated $3K sold.

Crosspoint Capital Strategies first reported a position in CRDF in Q4 2013 and held it in 2 quarters. The position peaked at $3K in Q1 2014. 21 funds tracked by Wall St. Rank hold CRDF as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining Cardiff Oncology position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 7 Cardiff Oncology shares in Q2 2014, an estimated $3K.
  • Crosspoint Capital Strategies first reported a position in Cardiff Oncology in Q4 2013 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Cardiff Oncology position peaked at $3K in Q1 2014.
  • 21 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.